INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 188 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $756,000 | -8.4% | 13,248 | -1.8% | 0.08% | +4.1% |
| Q1 2022 | $825,000 | +16.2% | 13,489 | -0.6% | 0.07% | +7.2% |
| Q4 2021 | $710,000 | +149.1% | 13,568 | +77.6% | 0.07% | +146.4% |
| Q3 2021 | $285,000 | -7.8% | 7,640 | +0.9% | 0.03% | -3.4% |
| Q2 2021 | $309,000 | +10.8% | 7,570 | -8.0% | 0.03% | -6.5% |
| Q1 2021 | $279,000 | +37.4% | 8,229 | +29.1% | 0.03% | +34.8% |
| Q4 2020 | $203,000 | – | 6,373 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |